U.S. to pay Pfizer, BioNTech $1.95 billion for COVID-19 vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE)
July 23, 2020 7:01 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) after speaking with a KOL about the company's hemophilia franchise. The doctor said that conventional thinking is that gene therapy will last 5-10 years, but... More
